Site Map    |    Contact    |  

Share | 

2014 News Releases

E-mail Alerts Receive E-mail Alerts  RSS RSS Feeds
Keyword Search
2014 | 2013 | 2012 | 2011 | 2010
DateTitle 
09/04/14Protalix BioTherapeutics to Present at the Rodman & Renshaw 16th Annual Global Investment ConferencePrinter Friendly Version
08/28/14Protalix Announces Conference Call to Discuss ELELYSO Pediatric Approval and Provide Updates on Additional ProgramsPrinter Friendly Version
08/28/14Pfizer And Protalix BioTherapeutics Announce FDA Approval Of Pediatric Indication For ELELYSO™ (taliglucerase alfa) For Injection, For Intravenous Use For The Treatment Of Type 1 Gaucher DiseasePrinter Friendly Version
07/24/14Protalix BioTherapeutics Names Shlomo Yanai as Chairman of the Board of DirectorsPrinter Friendly Version
06/27/14Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th MeetingPrinter Friendly Version
06/23/14Protalix BioTherapeutics Announces New Data on ELELYSO(TM) (taliglucerase alfa) and Oral GCD to be Presented at the European Working Group on Gaucher Disease 2014 11th MeetingPrinter Friendly Version
06/18/14Protalix BioTherapeutics Initiates Phase II Study With PRX-112, an Orally-Administered Enzyme Replacement Therapy for the Treatment of Gaucher DiseasePrinter Friendly Version
06/13/14Protalix BioTherapeutics' President and Chief Executive Officer, David Aviezer, Ph.D., Will Retire This YearPrinter Friendly Version
05/30/14Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Canada for the Treatment of Gaucher Disease in Both Adult and Pediatric PatientsPrinter Friendly Version
05/28/14Protalix BioTherapeutics to Present at Two Upcoming Healthcare ConferencesPrinter Friendly Version
05/22/14Protalix Announces ELELYSO(TM) (taliglucerase alfa) Approved in Australia for the Treatment of Gaucher Disease in Both Adult and Pediatric PatientsPrinter Friendly Version
05/07/14Protalix BioTherapeutics to Present at the Oppenheimer 15th Annual Israeli Conference and the MIXiii Israel Innovation Conference, BiomedPrinter Friendly Version
04/23/14Protalix Announces Data on Oral antiTNF to be Presented at Digestive Disease Week 2014 MeetingPrinter Friendly Version
02/12/14Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014Printer Friendly Version
02/06/14Protalix BioTherapeutics' Technology Transfer Agreement for UPLYSO(TM) (alfataliglicerase) With Brazil's Ministry of Health Approved by the Brazilian National Institute of Industrial PropertyPrinter Friendly Version
01/23/14Protalix Announces Successful Manufacturing Facility Evaluation by Health CanadaPrinter Friendly Version
01/13/14Protalix BioTherapeutics Provides Full-Year 2014 Strategic OutlookPrinter Friendly Version
01/07/14Protalix BioTherapeutics to Present at the 32nd Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version